These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19919555)

  • 21. Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.
    Costiniuk CT; Camacho F; Cooper CL
    Clin Infect Dis; 2008 Jul; 47(2):198-202. PubMed ID: 18532889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
    Bohlius J; Tonia T; Schwarzer G
    Acta Haematol; 2011; 125(1-2):55-67. PubMed ID: 21150188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor progression associated with erythropoiesis-stimulating agents.
    Newland AM; Black CD
    Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies for the Management of Postoperative Anemia in Elective Orthopedic Surgery.
    Steuber TD; Howard ML; Nisly SA
    Ann Pharmacother; 2016 Jul; 50(7):578-85. PubMed ID: 27147703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
    Szucs TD; Blank PR; Schwenkglenks M; Aapro M
    Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoietic stimulating agents.
    Testa U
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):119-38. PubMed ID: 20158404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older.
    Ibrahim HN; Ishani A; Guo H; Gilbertson DT
    Nephrol Dial Transplant; 2009 Oct; 24(10):3138-43. PubMed ID: 19451656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?
    Dahl NV; Henry DH; Coyne DW
    Semin Dial; 2008; 21(3):210-1. PubMed ID: 18397204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
    Singh A
    Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Transfusion requirements in chronic kidney disease].
    Frimat L
    Transfus Clin Biol; 2008 Nov; 15(5):214-6. PubMed ID: 18938100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing anemia management in hospitalized patients with end-stage renal disease.
    Heung M; Mueller BA; Segal JH
    Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
    Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
    Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
    Larson K
    Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
    Macdougall IC
    Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of erythropoiesis-stimulating agents in the treatment of anemia.
    Fishbane S
    Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives.
    Arcasoy MO
    Clin Cancer Res; 2008 Aug; 14(15):4685-90. PubMed ID: 18676735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes.
    Mundle SD
    Future Oncol; 2007 Aug; 3(4):397-403. PubMed ID: 17661714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.